Cited by 226Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentPsychedelics and Drug Studies

The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.

Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System

Emrich, Hinderk M, Leweke, F.Markus, Schneider, Udo·1997·Pharmacology Biochemistry and Behavior

Open this paper in CoChat — free account

Abstract

Cognitive impairments during psychotic episodes are assumed to be caused not only by one single putative classical neurotransmitter dysfunction but also by an impaired equilibrium of the interaction between different neurobiological generators of cognitive processes. Herein, the perceptual abnormalities induced by psychotogenic agents play a major role as tools for the understanding of model psychoses. The recently discovered cannabinoid receptor system with its endogenous ligand anandamide can be regarded as an extremely relevant regulator system, a dysfunctionality of which may explain at least one subtype of endogenous psychoses. Neuropsychological results (three-dimensional inversion illusion) in delta 9-tetrahydrocannabinol-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, regarding disturbances in internal regulation of perceptual processes. The relevance of this finding to a general cognitive dysfunction concept of schizophrenic psychosis is discussed.

Integrity signals

Registry

Crossref · 10.1016/s0091-3057(96)00426-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,862
Dopamine receptor pharmacology
Seeman, P. M., & Tol, H. H. M. V. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 969
BONE-MARROW TRANSPLANTATION IN A PATIENT WITH THE WISKOTT-ALDRICH SYNDROME
Bach, F. H., Albertini, R., Joo, P., Anderson, J., & Bortin, M. M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92672-x · Cited by 867
Health aspects of cannabis
Hollister, L. E. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90030-4 · Cited by 500
Significance and meaning of neurological signs in schizophrenia
Heinrichs, D. W., & Buchanan, R. W. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.1.11 · Cited by 433

Show all 35 references

Research works printed but not linked: 1

Schröder, 1993, Diskrete motorische und sensorische Störungen (neurologische soft signs) im Akutverlauf endogener Psychosen, Z. Klin. Psychol. Psychopathol. Psychother., 41, 190

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Cannabis and the brain
Iversen, L. L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 751
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 584
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., & Piomelli, D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300558 · Cited by 481
Self-citation
Elevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00008 · Cited by 431
Self-citation
Chronic Pubertal, but not Adult Chronic Cannabinoid Treatment Impairs Sensorimotor Gating, Recognition Memory, and the Performance in a Progressive Ratio Task in Adult Rats
Schneider, M., & Koch, M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300225 · Cited by 425
Cannabis as a risk factor for psychosis: Systematic review
Semple, D. M., McIntosh, A. M., & Lawrie, S. M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105049040 · Cited by 420
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders
van der Stelt, M., & Marzo, V. D. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 292
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283
Tests of causal linkages between cannabis use and psychotic symptoms
Fergusson, D. M., Horwood, L. J., & Ridder, E. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01001.x · Cited by 268
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia
Zavitsanou, K., Garrick, T. M., & Huang, X. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.005 · Cited by 270
Endocannabinoid signalling in the blood of patients with schizophrenia.
Marchi, N. D., PETROCELLIS, L. D., Orlando, P., Daniele, F., Fezza, F., & Marzo, V. D. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-5 · Cited by 266
Therapeutic Potential of Cannabinoids in CNS Disease
Croxford, J. L. (2003) · CNS Drugs · doi:10.2165/00023210-200317030-00004 · Cited by 241
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models
Malone, D. T., Hill, M. N., & Rubino, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00721.x · Cited by 237
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
Ujike, H., Takaki, M., Nakata, K., Tanaka, Y., Takeda, T., Kodama, M., Fujiwara, Y., Sakai, A., & Kuroda, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001029 · Cited by 232
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 227
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
Self-citation
The Science of Marijuana
Iversen, L. L. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328240.001.0001 · Cited by 230
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206
Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling
Dima, D., Roiser, J. P., Dietrich, D. E., Bonnemann, C., Lanfermann, H., Emrich, H. M., & Dillo, W. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.03.033 · Cited by 192
Self-citation
Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group
Assies, J., Lieverse, R., Vreken, P., WANDERS, R. J. A., Dingemans, P. M. A. J., & Linszen, D. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00986-0 · Cited by 188
Endocannabinoids in the central nervous system-an overview
Fride, E. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0360 · Cited by 186
What visual illusions teach us about schizophrenia
Notredame, C.-E., Pins, D., Deneve, S., & Jardri, R. (2014) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2014.00063 · Cited by 177
Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes
Bersani, G., Orlandi, V., Kotzalidis, G. D., & Pancheri, P. (2002) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-002-0366-5 · Cited by 176
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 150
Self-citation
Visual Perception Disturbances in Schizophrenia: A Unified Model
Silverstein, S. M. (2016) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-3-319-30596-7_4 · Cited by 147
A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission
Centonze, D., Battista, N., Rossi, S., Mercuri, N. B., Finazzi‐Agrò, A., Bernardi, G., Calabresi, P., & Maccarrone, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300458 · Cited by 145
From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis
Mechoulam, R., & Ben‐Shabat, S. (1999) · Natural Product Reports · doi:10.1039/a703973e · Cited by 145
Chronic (−)-Δ9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats
Gorriti, M. Á., de Fonseca, F. R., Navarro, M., & Palomo, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00851-6 · Cited by 137
Molecular biology of cannabinoid receptors
Lutz, B. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0342 · Cited by 138
Role of the endocannabinoid system in depression and suicide
Vinod, K. Y., & Hungund, B. L. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.08.006 · Cited by 132
Candidate genes for cannabis use disorders: findings, challenges and directions.
Agrawal, A., & Lynskey, M. T. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02504.x · Cited by 128
Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia
Müller‐Vahl, K., & Emrich, H. M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.7.1037 · Cited by 125
Self-citation
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Hallak, J. E. C., Machado‐de‐Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C. M. F., Chaves, C., Bernardo, S. A., Regalo, S. C. H., & Zuardi, A. W. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000100011 · Cited by 129
Impaired top-down processes in schizophrenia: a DCM study of ERPs
Dima, D., Dietrich, D. E., Dillo, W., & Emrich, H. M. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.086 · Cited by 122
Self-citation
Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation
Pálóczi, J., Varga, Z. V., Hasko, G., & Pacher, P. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7144 · Cited by 129
A review of abnormalities in the perception of visual illusions in schizophrenia
Griffiths-King, D. J., Hodgekins, J., Chouinard, P. A., Chouinard, V., & Sperandio, I. (2016) · Psychonomic Bulletin & Review · doi:10.3758/s13423-016-1168-5 · Cited by 112
Treatment of Tourette Syndrome with Delta-9-Tetrahydrocannabinol (Δ9-THC): No Influence on Neuropsychological Performance
Müller‐Vahl, K., Prevedel, H., Theloe, K., KOLBE, H., Emrich, H. M., & Schneider, U. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300047 · Cited by 111
Self-citation
Cannabinoids and the Brain
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
Reduced binocular depth inversion in schizophrenic patients
Schneider, U., Borsutzky, M., Seifert, J., Leweke, F. M., Huber, T. J., Rollnik, J. D., & Emrich, H. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00172-9 · Cited by 108
Self-citation
The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats
Schneider, M., & Koch, M. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200202000-00003 · Cited by 108
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats
Seillier, A., Advani, T., Cassano, T., Hensler, J. G., & Giuffrida, A. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570999023x · Cited by 105
Two cases of "cannabis acute psychosis" following the administration of oral cannabis
Favrat, B., Ménétrey, A., Augsburger, M. P., Rothuizen, L. E., Appenzeller, M., Buclin, T., Pin, M. A., Mangin, P. J., & Giroud, C. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-17 · Cited by 100
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Rohleder, C., Müller, J. K., Lange, B., & Leweke, F. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00422 · Cited by 94
Self-citation
New Perspectives in the Studies on Endocannabinoid and Cannabis: Cannabinoid Receptors and Schizophrenia
Ujike, H., & Morita, Y. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj04003x4 · Cited by 95
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Fišar, Z. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110626 · Cited by 103
Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness
Koethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., Emrich, H. M., Klosterkötter, J., Schultze-Lutter, F., & Leweke, F. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.023 · Cited by 93
Self-citation
Therapeutic Potential of Cannabinoids in Psychosis
Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.018 · Cited by 96
Self-citation
Perceptual instability in schizophrenia: Probing predictive coding accounts of delusions with ambiguous stimuli
Schmack, K., Schnack, A., Priller, J., & Sterzer, P. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.03.005 · Cited by 88
Cannabis‐induced psychosis: a cross‐sectional comparison with acute schizophrenia
Núñez, L. A., & Manuel Gurpegui, A. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.1o079.x · Cited by 91
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Merlos, M., & Garzón-Niño, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10095 · Cited by 87
Effects of acute oral Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers
Roser, P., Juckel, G., Rentzsch, J., Nadulski, T., Gallinat, J., & Stadelmann, A. M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.008 · Cited by 88
Cannabis and Neurological Soft Signs in Schizophrenia: Absence of Relationship and Influence on Psychopathology
Bersani, G., Orlandi, V., Gherardelli, S., & Pancheri, P. (2002) · Psychopathology · doi:10.1159/000067064 · Cited by 87
From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?
Skosnik, P. D., & Yao, J. K. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.08.008 · Cited by 86
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use
Xie, S., Furjanic, M. A., Ferrara, J., McAndrew, N. R., Ardino, E. L., Ngondara, A., Bernstein, Y., Thomas, K. J., Kim, E., Walker, J. M., et al. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00817.x · Cited by 82
Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function
Alonso, R., Voutsinos‐Porche, B., Fournier, M., Labie, C., Steinberg, R., Souilhac, J., Fur, G. L., & Soubrié, P. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00675-7 · Cited by 80
A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia
D’Addario, C., Micale, V., Bartolomeo, M. D., Štark, T., Pucci, M., Šulcová, A., Palazzo, C., Babinská, Z., Cremaschi, L., Drago, F., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.01.022 · Cited by 81
Accounting for the phenomenology and varieties of auditory verbal hallucination within a predictive processing framework
Wilkinson, S. (2014) · Consciousness and Cognition · doi:10.1016/j.concog.2014.09.002 · Cited by 81
The effect of Δ9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats
Malone, D. T., & TAYLOR, D. A. H. B. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.07.009 · Cited by 77
The role of Cannabinoids in neurodegenerative diseases
Glass, M. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00162-2 · Cited by 76
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
GUIMARAES, V. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.01.015 · Cited by 77
Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice
Nagai, H., Egashira, N., Sano, K., Ogata, A., Mizuki, A., Mishima, K., Iwasaki, K., Shoyama, Y., Nishimura, R., & Fujiwara, M. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.05.018 · Cited by 75
Reduced binocular depth inversion in regular cannabis users
Semple, D. M., Ramsden, F., & McIntosh, A. M. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00140-0 · Cited by 74
Psychophysiological Evidence of Altered Neural Synchronization in Cannabis Use: Relationship to Schizotypy
Skosnik, P. D., Krishnan, G. P., Aydt, E. E., Kuhlenshmidt, H. A., & O’Donnell, B. F. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1798 · Cited by 72
Cannabis and psychosis: an update on course and biological plausible mechanisms
LINSZEN, D. H., & van Amelsvoort, T. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32803577fb · Cited by 71
Psychosis and synthetic cannabinoids
Deng, H., Verrico, C. D., Kosten, T. R., & Nielsen, D. A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.012 · Cited by 68
Acute effects of Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity
Juckel, G., Roser, P., Nadulski, T., Stadelmann, A. M., & Gallinat, J. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.015 · Cited by 64
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
Roser, P., Vollenweider, F. X., & Kawohl, W. (2008) · The World Journal of Biological Psychiatry · doi:10.3109/15622970801908047 · Cited by 69
The endocannabinoid system: a physiological perspective on its role in psychomotor control
Giuffrida, A., & Piomelli, D. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00193-6 · Cited by 63
Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia
SCHWARCZ, G., Karajgi, B. M., & McCarthy, R. H. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a6bc3b · Cited by 62
Cannabis-Associated Psychosis
Leweke, F. M., Gerth, C. W., & tter, J. K. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00005 · Cited by 60
Self-citation
Current pharmacological models of social withdrawal in rats
Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833fa7df · Cited by 59
Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy
Potvin, S., Kouassi, É., Lipp, O., Bouchard, R.-H., Roy, M., Demers, M., Gendron, A., Astarita, G., Piomelli, D., & Stip, É. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083816 · Cited by 59
The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling
Robinson, S. A., Loiacono, R. E., Christopoulos, A., Sexton, P. M., & Malone, D. T. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.031 · Cited by 57
Phytocannabinoids and Endocannabinoids
Fišar, Z. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902010051 · Cited by 57
Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide
González, S. R., Romero, J., de Miguel, R., Lastres‐Becker, I., Villanúa, M. A., Makriyannis, A., Ramos, J. A., & Fernández‐Ruíz, J. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00251-9 · Cited by 56
Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists
Hill, M. N., Froese, L. M., Morrish, A. C., Sun, J. C., & Floresco, S. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0421-4 · Cited by 57
Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
Roser, P., Gallinat, J., Weinberg, G., Juckel, G., Gorynia, I., & Stadelmann, A. M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0868-5 · Cited by 60
[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients
Berding, G., Müller-Vahl, K., Schneider, U., Gielow, P., Fitschen, J., Stuhrmann, M., Harke, H., Buchert, R., Donnerstag, F., Hofmann, M., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.005 · Cited by 54
Self-citation
Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 52
Is the perception of illusions abnormal in schizophrenia?
Grzeczkowski, L., Roinishvili, M., Chkonia, E. D., Brand, A., Mast, F. W., Herzog, M. H., & Shaqiri, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.063 · Cited by 51
Modulation of cannabinoid agonist binding by 5‐HT in the rat cerebellum
Devlin, M. G., & Christopoulos, A. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00797.x · Cited by 51
Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy
Voicu, V. A., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Corlatescu, A.-D., Bordeianu, A., Costin, H. P., Bratu, B.-G., Glavan, L.-A., & Ciurea, A. V. (2023) · Biomolecules · doi:10.3390/biom13091388 · Cited by 52
Drugs of abuse and increased risk of psychosis development
Gururajan, A., Manning, E. E., Klug, M., & van den Buuse, M. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412455232 · Cited by 50
The Neuropsychology of Cannabis and other Substance use in Schizophrenia: Review of the Literature and Critical Evaluation of Methodological Issues
Coulston, C. M., Perdices, M., & Tennant, C. C. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701634952 · Cited by 48
Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations.
Edwards, C. R., Skosnik, P. D., Steinmetz, A. B., O’Donnell, B. F., & Hetrick, W. P. (2009) · Behavioral Neuroscience · doi:10.1037/a0016328 · Cited by 47
Alterations of Consciousness: An Empirical Analysis for Social Scientists
Barušs, I. (2003) · Choice Reviews Online · doi:10.5860/choice.41-1233 · Cited by 59
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
Leweke, F. M., Mueller, J. K., Lange, B., Fritze, S., Topor, C. E., Koethe, D., & Rohleder, C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0539-z · Cited by 48
Self-citation
Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies
Ganesh, S., Cortes-Briones, J., Ranganathan, M., Radhakrishnan, R., Skosnik, P. D., & D’Souza, D. C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa031 · Cited by 44
Affect processing and positive syndrome schizotypy in cannabis users
Skosnik, P. D., Park, S., Dobbs, L., & Gardner, W. L. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.010 · Cited by 41
Auditory gating in rat hippocampus and medial prefrontal cortex: Effect of the cannabinoid agonist WIN55,212-2
Dissanayake, D. W. N., Zachariou, M., Marsden, C. A., & Mason, R. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.039 · Cited by 41
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
Ľupták, M., Michaličková, D., Fišar, Z., Kitzlerová, E., & Hroudová, J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.277 · Cited by 41
Cannabinoid Receptors and Their Relationships with Neuropsychiatric Disorders
Gambi, F., Berardis, D. D., Sepede, G., Quartesan, R., Calcagni, E., Salerno, R. M., Conti, C. M., & Ferro, F. M. (2005) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200501800103 · Cited by 41
Lipids in health and disease
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 41
Pharmacological and molecular targets in the search for novel antipsychotics
Scatton, B., & Sanger, D. J. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00008 · Cited by 39
CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice
Khella, R., Short, J. L., & Malone, D. T. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3481-x · Cited by 38

Authors: Emrich, H. M., Leweke, F. M., & Schneider, U.
Affiliations: Medizinische Hochschule Hannover (DE)
Corresponding author: Emrich, Hinderk M
ORCID: Leweke, F.Markus
Schneider, Udo
Venue: Pharmacology Biochemistry and Behavior
Publisher: Elsevier BV
Published: 1997-04
Volume: 56
Issue: 4
Pages: 803-807
ISSN: 0091-3057 (ISSN-L)
DOI: 10.1016/s0091-3057(96)00426-1
OpenAlex: W1986173065
Cited by: 226
References: 35
Citations by year: 2025: 2 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 16 · 2017: 7 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 3 · 2012: 8
FWCI: 5.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology Biochemistry and Behavior (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords: schizophrenia, endocannabinoid system, anandamide, cognitive impairment, perceptual disorders, cannabinoid receptors, psychosis
MeSH terms: Adult, Cannabinoids, Depth Perception, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Receptors, Drug, Schizophrenia, Schizophrenic Psychology, Vision, Binocular, Receptors, Cannabinoid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks